Immunomic Therapeutics

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Immunomic Therapeutics sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).

6 total trials 1 currently recruiting 4 completed early-phase tilt upper quartile by trial count

Immunomic Therapeutics: 6 sponsored US clinical trials, 1 recruiting.

Immunomic Therapeutics sponsors 6 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 4 completed. 0 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Allergic Rhinitis, with 1 trials.

Upper-quartile sponsor footprint

Immunomic Therapeutics sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Open and recent trials

6 total, page 1 of 1

RECRUITING Phase 1

First-in-human, Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) Alone or in Combination With Pembrolizumab in Stage II-- III Triple Negative Breast Cancer Following Standard Therapy ( VITAL-TNBC )

NCT07652242
ACTIVE NOT RECRUITING Phase 1

Study to Evaluate the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of ITI-1001 In Patients With Newly Diagnosed Glioblastoma (GBM)

NCT05698199
COMPLETED Phase 1

Study To Evaluate The Safety, Tolerability And Immunogenicity Of 4 mg Of ITI-3000 In Patients With Polyomavirus-Positive Merkel Cell Carcinoma (MCC)

NCT05422781
COMPLETED Phase 1

A Safety and Immunogenicity Phase IC Study of CryJ2 -DNA-LAMP Plasmid Vaccine for Assessment of Intradermal (ID) Route of Administration Using the Biojector 2000 Device

NCT02146781
COMPLETED Phase 1

A Safety and Immunogenicity Phase IB Study of CryJ2-DNA-Lysosomal Associated Membrane Protein (CryJ2 -DNA-LAMP) Plasmid Assessing the Long Term Safety of Previously Treated Subjects

NCT01966224
COMPLETED Phase 1

A Safety and Immunogenicity Phase I Study of CryJ2-DNA-Lysosomal Associated Membrane Protein (CryJ2 -DNA-LAMP) Plasmid

NCT01707069

Phase Distribution

PhaseTrial count
Phase 1 6

Therapeutic Areas

Allergic Rhinitis 1
Glioblastoma 1

What is open in the Immunomic Therapeutics pipeline

1 recruiting of 6 indexed (17% open); 4 completed (67%).

Phase mix: 0 late (III/IV) vs 6 early (I/II) (early-phase heavy).

Top condition: Allergic Rhinitis (1 trial), 1 other listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Immunomic Therapeutics: open-pipeline peers nationwide

Peers matched on 6 registered trials and 17% open enrollment, not the therapeutic-area sidebar.

Immunomic Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 468101214 0%20%40%60%80% Total trials Recruiting share Immunomic Therapeutics23andMeAardvark TherapeuticsAbbisko Therapeutics CoAbGenomics B.V Taiwan BranchAdageneAgendiaAkamis BioAngiodynamics
Immunomic Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Immunomic Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 6 trials (± recruiting share)

Sponsors near 17% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Immunomic Therapeutics page

6 registered trials is a research-attention snapshot, not an endorsement of Immunomic Therapeutics or any single study.

  • 1 of Immunomic Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Allergic Rhinitis is the condition Immunomic Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Allergic Rhinitis trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Immunomic Therapeutics pipeline card: 6 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.